Phase III Daclatasvir + Sofosbuvir in Cirrhotic Subjects and Subjects Post-liver Transplant

Updated Jan 2014
Related:
Daclatasvir and Sofosbuvir: New drug combo cures toughest cases of hepatitis C, hints to future injection-free therapies

Background Information - Daclatasvir Plus Sofosbuvir

View additional hepatitis trials updated in the last 30 days @ ClinicalTrials.gov

Very exciting!!

Phase III Daclatasvir + Sofosbuvir in Cirrhotic Subjects and Subjects Post-liver Transplant (ALLY 1)

This study is not yet open for participant recruitment. 

Verified January 2014 by Bristol-Myers Squibb
Sponsor: Bristol-Myers Squibb
Information provided by (Responsible Party): Bristol-Myers Squibb

Condition:	Hepatitis C
Interventions:	Drug: Daclatasvir;   Drug: Sofosbuvir;   Drug: Ribavirin
Phase:	Phase 3
NCT Number:	NCT02032875
Study Start:	March 2014

Purpose
This trial is open to patients with cirrhosis due to chronic HCV, and to patients who have already received a liver transplant for chronic HCV. All subjects will be treated with Daclatasvir and Sofosbuvir for 12 weeks. Under certain conditions, the treatment duration may be extended for cirrhotic subjects. The study will test how well this combination of investigational drugs works to treat chronic HCV.

Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV (ALLY 3)

This study is not yet open for participant recruitment.
 
Verified January 2014 by Bristol-Myers Squibb
Sponsor: Bristol-Myers Squibb
Information provided by (Responsible Party): Bristol-Myers Squibb

Condition:	Hepatitis C
Interventions:	Drug: Daclatasvir;   Drug: Sofosbuvir
Phase:	Phase 3
NCT Number:	NCT02032901
Study Start:	February 2014

Purpose
To study the combination of Daclatasvir and Sofosbuvir for the treatment of HCV Genotype 3 infection

Phase III HIV/HCV Co-Infection Daclatasvir (DCV)+ Sofosbuvir (SOF) (ALLY 2)

This study is not yet open for participant recruitment. 

Verified January 2014 by Bristol-Myers Squibb
Sponsor:Bristol-Myers Squibb
Information provided by (Responsible Party):Bristol-Myers Squibb

Condition:	Hepatitis C
Interventions:	Drug: Daclatasvir;   Drug: Sofosbuvir
Phase:	Phase 3
NCT Number:	NCT02032888
Study Start:	February 2014

Purpose
To study the combination of Daclatasvir and Sofosbuvir for the treatment of HCV/ HIV Coinfection